Remove tag personalised-healthcare
article thumbnail

A broad range of unmet needs remains in the immuno-oncology space

Pharmaceutical Technology

The unmet needs can be grouped into the broad categories of efficacy-related needs, cost-related needs, toxicity-related needs, personalised care-related needs, and “other” needs. IO therapies come with a hefty price tag, with ICI therapies in the US typically exceeding $100,000, while cell therapies can exceed $400,000.

article thumbnail

What can pharma marketing learn from other regulated industries?

pharmaphorum

In this article Joanna Carlish, managing director of financial services at Tag Americas , and Robb DeFilippis, Tag Americas’ managing director, life sciences, go head-to-head to discuss marketing within a regulated industry. Personalising marketing content. Virtual connections.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Grand Rounds April 21, 2023: Personalised Cooler Dialysate for Patients Receiving Maintenance Haemodialysis (MyTEMP): A Pragmatic, Cluster-randomised Trial (Amit Garg, MD, MA, FRCPC, FACP, PhD; Stephanie N. Dixon, PhD MSc)

Rethinking Clinical Trials

MyTEMP was innovative and pragmatic, implemented as part of a learning healthcare system, with covariate constrained randomization, registry-based, and embedded in routine care delivered by more than 2,000 nurses at 84 centers. As a clinician when I am providing care, I’m not discussing these concerns; we are talking about other things.

Trials 130
article thumbnail

3 ways pharma marketers can draw inspiration from digitally-native brands

pharmaphorum

This gives them huge amounts of customer data that allows them to shape and personalise the way they engage with their customers, not least thanks to the direct-to-consumer sales model they often offer. Jeremy Richter, Tag. Joe adds: “Digitally-native brands also have a laser focus on the channels they’re executing for.

Branding 110
article thumbnail

Roche’s anti-amyloid beta antibody gantenerumab granted FDA Breakthrough Therapy Designation in Alzheimer’s disease

The Pharma Data

This designation is predicated on data showing that gantenerumab significantly reduced brain amyloid pillar, a pathological hallmark of Notice, in the ongoing SCarlet RoAD and Marguerite RoAD open- tag extension trials, as well as other studies. Both trials are expected to be completed in the second half of 2022.

article thumbnail

New to ELRIG Drug Discovery 2022: Tech Theatre supported by DDW

Drug Discovery World

will discuss The role of AI and Automation in Personalised Medicine: How can AI Help in the Post- Drug Discovery Process. Dr Anvar was a senior scientist before joining OKRA, serving as the principal investigator of preclinical personalised medicine. Dr Yahya Anvar, Head of Data Science, OKRA.ai

Drugs 52
article thumbnail

What is modular content and why do pharma marketers need it NOW?

pharmaphorum

Modular content is an established practice among digital and content marketers in sectors such as FMCG and retail, who are challenged with increasing demand for more content and creating personalised content to meet the demands of their customers. A modular content ecosystem.